Compare AU
Compare VAS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Australian Shares Index ETF (VAS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VAS | CURE | |
|---|---|---|
Popularity | High | Low |
Pearlers invested | 18,609 | 82 |
Median incremental investment | $1,002.95 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,863.84 | $1,323.41 |
Average age group | 26 - 35 | > 35 |
Key Summary
VAS | CURE | |
|---|---|---|
Strategy | Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BHP Group Ltd. (10.36 %) Commonwealth Bank of Australia (7.92 %) CSL Ltd. (5.76 %) | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) |
Top 3 industries | Financials (27.66 %) Materials (23.74 %) Health Care (8.77 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (94.56 %) United States (3.02 %) New Zealand (1.65 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.07 % | 0.45 % |
Key Summary
VAS | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | S&P/ASX 300 Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.07 % | 0.45 % |
Price | $102.28 | $49.94 |
Size | N/A | $38.065 million |
10Y return | 46.28 % | N/A |
Annual distribution yield (5Y) | 5.52 % | 4.24 % |
Market | ASX | ASX |
First listed date | 08/05/2009 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VAS | CURE | |
|---|---|---|
Popularity | High | Low |
Pearlers invested | 18,609 | 82 |
Median incremental investment | $1,002.95 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,863.84 | $1,323.41 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
VAS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VAS | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |